<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Peter Mas-Mollinedo, Author at Pharmacy Update Online</title>
	<atom:link href="https://pharmacyupdateonline.com/author/petermas/feed/" rel="self" type="application/rss+xml" />
	<link>https://pharmacyupdateonline.com/author/petermas/</link>
	<description></description>
	<lastBuildDate>Tue, 06 Oct 2026 12:19:59 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.5</generator>

<image>
	<url>https://pharmacyupdateonline.com/wp-content/uploads/2020/12/cropped-favicon-512x360.png</url>
	<title>Peter Mas-Mollinedo, Author at Pharmacy Update Online</title>
	<link>https://pharmacyupdateonline.com/author/petermas/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Nineteen treatments recommended as CHMP delivers broad September approvals cycle</title>
		<link>https://pharmacyupdateonline.com/2026/10/nineteen-treatments-recommended-as-chmp-delivers-broad-september-approvals-cycle/</link>
		
		<dc:creator><![CDATA[Peter Mas-Mollinedo]]></dc:creator>
		<pubDate>Tue, 06 Oct 2026 12:19:59 +0000</pubDate>
				<category><![CDATA[Legislative & Regulatory]]></category>
		<category><![CDATA[Medicines & Therapeutics]]></category>
		<category><![CDATA[Practices & Services]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[drug approvals]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[multiple myeloma]]></category>
		<category><![CDATA[ovarian cancer]]></category>
		<category><![CDATA[spondyloarthritis]]></category>
		<guid isPermaLink="false">https://pharmacyupdateonline.com/?p=22592</guid>

					<description><![CDATA[<p>The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued nineteen positive recommendations between 17 and 21 September 2026, spanning oncology, rheumatology, dermatology, neurology, [&#8230;]</p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/10/nineteen-treatments-recommended-as-chmp-delivers-broad-september-approvals-cycle/">Nineteen treatments recommended as CHMP delivers broad September approvals cycle</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><strong>The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued nineteen positive recommendations between 17 and 21 September 2026, spanning oncology, rheumatology, dermatology, neurology, haematology, ophthalmology, gastroenterology, and infectious disease. The September cycle is one of the most wide-ranging of the year, with multiple myeloma, ovarian cancer, and spondyloarthritis each featuring more than once, alongside a notable biosimilar recommendation for omalizumab that will broaden patient access to a well-established biologic therapy.</strong></p>
<p>The cycle also includes two significant first-in-class or novel-mechanism approvals: a subcutaneous formulation of ocrelizumab for multiple sclerosis offering a faster administration option compared with the established intravenous infusion, and gefurulimab, a new complement inhibitor for myasthenia gravis. Rheumatology features prominently, with filgotinib receiving two separate recommendations for related but distinct forms of spondyloarthritis in the same cycle.</p>
<h2><strong>Oncology</strong></h2>
<p><strong>Enhertu recommended for HER2-positive breast cancer</strong></p>
<p>Fam-trastuzumab deruxtecan (Enhertu), developed by Daiichi Sankyo and AstraZeneca, received a CHMP recommendation on 18 September 2026 for HER2-positive breast cancer. Enhertu is a HER2-directed antibody-drug conjugate that has transformed the treatment landscape across multiple HER2-expressing tumour types. This recommendation reflects the continued expansion of its approved indications in breast cancer, building on earlier approvals for HER2-low and HER2-ultralow disease. The drug’s high drug-to-antibody ratio and membrane-permeable payload contribute to a bystander effect that may benefit tumours with heterogeneous HER2 expression.</p>
<p><strong>Keytruda and Padcev combination recommended for muscle-invasive bladder cancer</strong></p>
<p>Pembrolizumab (Keytruda) in combination with enfortumab vedotin (Padcev), submitted by Merck, Astellas, and Pfizer, received a CHMP recommendation on 18 September 2026 for muscle-invasive bladder cancer. This combination pairs a PD-1 checkpoint inhibitor with a Nectin-4-directed antibody-drug conjugate, targeting both immune evasion and tumour cell proliferation. The recommendation follows strong clinical evidence supporting this chemotherapy-free regimen as a front-line treatment option, extending its reach in urothelial cancer beyond the metastatic setting in which it was first established.</p>
<p><strong>Ensacove recommended for ALK-positive non-small cell lung cancer</strong></p>
<p>Ensartinib (Ensacove), an ALK inhibitor developed by Xcovery and Betta Pharmaceuticals, received a CHMP recommendation on 17 September 2026 for ALK-positive non-small cell lung cancer (NSCLC). ALK rearrangements are present in approximately three to five per cent of NSCLC cases and define a molecularly distinct subgroup that is highly sensitive to ALK-directed therapy. Ensartinib is a next-generation ALK inhibitor with activity against several resistance mutations that limit the efficacy of earlier agents in this class, offering an additional treatment option in a landscape already served by crizotinib, alectinib, brigatinib, and lorlatinib.</p>
<p><strong>Tecvayli recommended for multiple myeloma</strong></p>
<p>Teclistamab (Tecvayli), a BCMA/CD3 bispecific T-cell engager developed by Janssen Biotech, received a CHMP recommendation on 17 September 2026 for relapsed or refractory multiple myeloma. Tecvayli redirects cytotoxic T cells to BCMA-expressing myeloma cells, offering a chemotherapy-free immunological approach for patients who have exhausted prior lines of therapy. The recommendation adds to an increasingly complex therapeutic landscape in myeloma, which now includes proteasome inhibitors, immunomodulatory drugs, anti-CD38 monoclonal antibodies, BCMA-directed ADCs, and CAR-T therapies.</p>
<p><strong>Pepaxto recommended for multiple myeloma</strong></p>
<p>Melflufen in combination with dexamethasone (Pepaxto), developed by Oncopeptides, received a CHMP recommendation on 17 September 2026 for relapsed or refractory multiple myeloma. Melflufen is a peptide-drug conjugate that is selectively taken up by myeloma cells and cleaved intracellularly to release a cytotoxic alkylating agent. The agent targets a patient population with heavily pretreated, late-line disease, and its approval provides an additional option where treatment choices are often limited by prior exposure and resistance to established drug classes.</p>
<p><strong>Lifyorli and Abraxane combination recommended for ovarian cancer</strong></p>
<p>Relacorilant in combination with nab-paclitaxel (Lifyorli and Abraxane), submitted by Corcept Therapeutics, received a CHMP recommendation on 18 September 2026 for platinum-resistant ovarian cancer. Relacorilant is a selective glucocorticoid receptor modulator that blocks the pro-survival signalling that glucocorticoids can induce in tumour cells, potentially overcoming a mechanism of resistance to taxane-based chemotherapy. The combination represents a novel approach to a cancer type in which platinum resistance is a significant clinical challenge, and where effective second-line options remain limited.</p>
<p><strong>Sepalna recommended for ovarian cancer</strong></p>
<p>Senaparib (Sepalna), a PARP inhibitor developed by IMPACT Therapeutics and partnered with SFL Pharmaceuticals, received a CHMP recommendation on 17 September 2026 for ovarian cancer. PARP inhibitors exploit deficiencies in DNA repair pathways — particularly homologous recombination deficiency associated with BRCA mutations — to selectively kill cancer cells. Sepalna adds to an established class that includes olaparib, niraparib, and rucaparib, and its approval provides a further PARP inhibitor option for eligible patients across the ovarian cancer treatment continuum.</p>
<h2><strong>Rheumatology &amp; Immunology</strong></h2>
<p><strong>Jyseleca recommended for ankylosing spondylitis and axial spondyloarthritis</strong></p>
<p>Filgotinib (Jyseleca), a selective JAK1 inhibitor developed by Eisai and Alfasigma, received two separate CHMP recommendations on 17 September 2026: one for ankylosing spondylitis (AS) and a second for non-radiographic axial spondyloarthritis (nr-axSpA), together covering the full spectrum of axial spondyloarthritis. AS is the radiographically confirmed form of axial SpA characterised by structural changes to the sacroiliac joints and spine, while nr-axSpA describes the earlier or less structurally severe presentation. The dual recommendation reflects the breadth of filgotinib’s clinical evidence across these related conditions, extending its established use in rheumatoid arthritis and ulcerative colitis into a further inflammatory rheumatological indication.</p>
<p><strong>Cosentyx recommended for polymyalgia rheumatica</strong></p>
<p>Secukinumab (Cosentyx), an anti-interleukin-17A monoclonal antibody developed by Novartis, received a CHMP recommendation on 18 September 2026 for polymyalgia rheumatica (PMR). PMR is a common inflammatory condition in older adults causing pain and stiffness in the shoulders, neck, and hips, and is currently managed primarily with long-term corticosteroid therapy, which carries significant cumulative side effects. Secukinumab is already approved for multiple immune-mediated inflammatory conditions including psoriasis, ankylosing spondylitis, and psoriatic arthritis; this recommendation in PMR represents a meaningful addition for a patient group in which steroid-sparing treatments are greatly needed.</p>
<h2><strong>Dermatology</strong></h2>
<p><strong>Anzupgo recommended for atopic dermatitis</strong></p>
<p>Delgocitinib (Anzupgo), a pan-JAK inhibitor developed by Japan Tobacco and Leo Pharma in a topical formulation, received a CHMP recommendation on 17 September 2026 for moderate to severe atopic dermatitis in adults. Topical JAK inhibitors represent an emerging class in atopic dermatitis that offer targeted anti-inflammatory activity at the site of application while minimising systemic exposure. Delgocitinib inhibits all four JAK isoforms and has demonstrated efficacy in patients with disease inadequately controlled by topical corticosteroids, providing a steroid-sparing alternative for chronic or difficult-to-manage disease.</p>
<p><strong>Povofortay recommended for hidradenitis suppurativa</strong></p>
<p>Povorcitinib (Povofortay), a selective JAK1 inhibitor developed by Incyte Corporation, received a CHMP recommendation on 17 September 2026 for hidradenitis suppurativa (HS), a chronic inflammatory skin condition characterised by recurrent painful nodules, abscesses, and scarring in the axillae, groin, and other intertriginous areas. HS is frequently debilitating and has historically been difficult to treat, with biologics targeting TNF-alpha and IL-17 offering only partial responses in many patients. Povorcitinib provides the first oral JAK inhibitor option in HS and may address patients who have an inadequate response to or cannot tolerate existing biologic therapies.</p>
<h2><strong>Neurology &amp; Immunology</strong></h2>
<p><strong>Ocrevus subcutaneous formulation recommended for multiple sclerosis</strong></p>
<p>A subcutaneous formulation of ocrelizumab (Ocrevus SC), developed by Roche, Biogen, and Genentech, received a CHMP recommendation on 17 September 2026 for relapsing and primary progressive multiple sclerosis. Ocrelizumab is a CD20-directed B-cell depleting monoclonal antibody already widely used in its intravenous form, which requires administration by healthcare professionals in a clinical setting over several hours. The subcutaneous formulation offers a faster injection that may be suitable for home or self-administration in eligible patients, representing a meaningful advance in convenience and healthcare resource use without compromising efficacy.</p>
<p><strong>Klygefa recommended for myasthenia gravis</strong></p>
<p>Gefurulimab (Klygefa), a complement C2 inhibitor developed by Alexion Pharmaceuticals and AstraZeneca, received a CHMP recommendation on 18 September 2026 for generalised myasthenia gravis. Complement pathway inhibition is an established mechanism in myasthenia gravis, with anti-C5 agents already approved in this setting. Gefurulimab targets C2, an upstream component of both the classical and lectin pathways, offering a potentially broader complement blockade. The recommendation adds a further mechanistic option to a disease area that has seen rapid therapeutic development in recent years.</p>
<h2><strong>Haematology &amp; Paediatrics</strong></h2>
<p><strong>Frehemgo recommended for haemophilia A</strong></p>
<p>Denecimig (Frehemgo), a novel bispecific antibody developed by Novo Nordisk, received a CHMP recommendation on 17 September 2026 for haemophilia A, including in paediatric patients. Denecimig mimics the cofactor function of factor VIII by bridging activated factor IX and factor X, enabling the coagulation cascade to proceed in the absence of endogenous factor VIII. The approach offers an alternative to factor replacement therapy that may be particularly valuable for patients with inhibitors — antibodies that neutralise infused factor VIII and render standard replacement therapy ineffective. The once-weekly subcutaneous administration route also offers a practical advantage over intravenous factor concentrate infusions.</p>
<p><strong>Adcomfo biosimilar recommended for allergic asthma, urticaria, and nasal polyps</strong></p>
<p>Adcomfo, a biosimilar of omalizumab developed by Alvotech and Advanz Pharma, received a CHMP recommendation on 17 September 2026 for allergic asthma, chronic spontaneous urticaria, and chronic rhinosinusitis with nasal polyps. Omalizumab is an anti-IgE monoclonal antibody that reduces the allergic inflammatory response and is already established across these three indications in its originator form (Xolair). As the first omalizumab biosimilar to receive a CHMP recommendation, Adcomfo is expected to increase competition in the market and improve patient access by reducing treatment costs across EU healthcare systems.</p>
<h2><strong>Ophthalmology</strong></h2>
<p><strong>Susvimo implant recommended for age-related macular degeneration</strong></p>
<p>The ranibizumab 100 mg/mL intravitreal implant (Susvimo), developed by Genentech/Roche and Novartis, received a CHMP recommendation on 21 September 2026 for neovascular (wet) age-related macular degeneration (AMD). Susvimo is a surgically implanted ocular device that delivers a continuous, sustained release of ranibizumab directly into the vitreous, avoiding the need for frequent intravitreal injections that characterise standard anti-VEGF therapy for wet AMD. The recommendation, which mirrors a decision also taken at the EU level this cycle, positions Susvimo as a long-term management option for patients with wet AMD who would benefit from a reduced injection burden.</p>
<h2><strong>Gastroenterology</strong></h2>
<p><strong>Zeydovio recommended for short bowel syndrome</strong></p>
<p>Glepaglutide (Zeydovio), a long-acting GLP-2 receptor agonist developed by Zealand Pharma, received a CHMP recommendation on 18 September 2026 for short bowel syndrome (SBS) in adults. SBS is a rare and debilitating condition resulting from the surgical removal or congenital absence of a significant portion of the small intestine, leaving patients dependent on parenteral nutrition for survival. GLP-2 receptor agonists promote intestinal adaptation by stimulating mucosal growth and improving absorptive capacity, with the goal of reducing or eliminating dependence on parenteral nutrition. Glepaglutide’s once-weekly dosing schedule, made possible by its extended half-life, offers a significant practical advantage over the twice-daily injections required with teduglutide, the existing approved GLP-2 analogue in this indication.</p>
<h2><strong>Infectious Diseases</strong></h2>
<p><strong>VaxRabeo recommended for rabies prevention</strong></p>
<p>VaxRabeo, an inactivated rabies vaccine developed by Sanofi Winthrop Industrie, received a CHMP recommendation on 17 September 2026 for the pre- and post-exposure prevention of rabies. Rabies remains a significant cause of mortality globally, particularly in parts of Asia and Africa, and EU travellers to endemic regions require access to reliable pre-exposure prophylaxis. The recommendation for VaxRabeo adds to the existing portfolio of approved rabies vaccines available within the EU and ensures continued supply of this important public health intervention.</p>
<p><em>All nineteen decisions listed carry CHMP Recommended status and were issued between 17–21 September 2026. CHMP recommendations are subject to final marketing authorisation by the European Commission. This article is based on data from the European Medicines Agency CHMP opinion cycle.</em></p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/10/nineteen-treatments-recommended-as-chmp-delivers-broad-september-approvals-cycle/">Nineteen treatments recommended as CHMP delivers broad September approvals cycle</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Three treatments approved by NICE in September, with one negative decision</title>
		<link>https://pharmacyupdateonline.com/2026/10/three-treatments-approved-by-nice-in-september-with-one-negative-decision/</link>
		
		<dc:creator><![CDATA[Peter Mas-Mollinedo]]></dc:creator>
		<pubDate>Tue, 06 Oct 2026 12:02:30 +0000</pubDate>
				<category><![CDATA[Genetics]]></category>
		<category><![CDATA[Legislative & Regulatory]]></category>
		<category><![CDATA[Medicines & Therapeutics]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Practices & Services]]></category>
		<category><![CDATA[drug approvals]]></category>
		<category><![CDATA[endometrial cancer]]></category>
		<category><![CDATA[Gomekli]]></category>
		<category><![CDATA[Imfinzi]]></category>
		<category><![CDATA[neurofibromatosis type 1]]></category>
		<category><![CDATA[NICE]]></category>
		<guid isPermaLink="false">https://pharmacyupdateonline.com/?p=22589</guid>

					<description><![CDATA[<p>The National Institute for Health and Care Excellence (NICE) has issued four Technology Appraisal decisions in September 2026, comprising three positive first recommendations and one negative decision. Decisions [&#8230;]</p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/10/three-treatments-approved-by-nice-in-september-with-one-negative-decision/">Three treatments approved by NICE in September, with one negative decision</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><strong>The National Institute for Health and Care Excellence (NICE) has issued four Technology Appraisal decisions in September 2026, comprising three positive first recommendations and one negative decision. Decisions were issued between 9 and 23 September 2026 and span oncology, neurology, haematological cancer, and dermatology. Though a smaller cycle than some preceding months, the decisions include a notable first approved treatment for neurofibromatosis type 1-associated plexiform neurofibromas in children and adults, and a significant combination regimen in endometrial cancer that may reshape standard-of-care treatment in that setting.</strong></p>
<p>The single negative decision — for nemolizumab in prurigo nodularis — reflects the ongoing challenge of demonstrating cost-effectiveness for treatments targeting rare and highly burdensome skin conditions, despite clear clinical evidence of benefit.</p>
<h2><strong>Positive Recommendations</strong></h2>
<p><strong>Gomekli recommended for neurofibromatosis type 1 — a first approved treatment</strong></p>
<p>Mirdametinib (Gomekli), developed by Springworks Therapeutics and MerckKGaA, received a positive NICE recommendation on 16 September 2026 for neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas in adults and children. NF1 is a rare inherited genetic condition caused by mutations in the NF1 tumour suppressor gene, leading to uncontrolled cell growth in nerve tissue. Plexiform neurofibromas are benign but often disfiguring and functionally impairing tumours that can cause chronic pain, neurological deficits, and airway compression depending on their location, and have historically been managed primarily through surgery. Mirdametinib is a selective MEK1/2 inhibitor that targets the RAS/MAPK signalling pathway activated by loss of neurofibromin, the protein encoded by the NF1 gene. The recommendation represents a landmark moment for the NF1 community, providing the first approved oral systemic therapy for this manifestation of the condition on the NHS.</p>
<p><strong>Imfinzi combination recommended for endometrial cancer</strong></p>
<p>Durvalumab (Imfinzi) in combination with carboplatin and paclitaxel chemotherapy, with or without olaparib (Lynparza), was recommended by NICE on 9 September 2026 for advanced or recurrent endometrial cancer. Submitted by AstraZeneca, this regimen reflects the emerging stratified approach to endometrial cancer treatment, in which the addition of a PARP inhibitor such as olaparib is directed at patients whose tumours show homologous recombination deficiency or specific molecular features. Durvalumab is a PD-L1 checkpoint inhibitor that augments the anti-tumour immune response alongside the cytotoxic effects of platinum-based chemotherapy. The recommendation positions this combination as a new standard-of-care option in a disease where systemic treatment outcomes have historically been poor in the relapsed or advanced setting.</p>
<p><strong>Imbruvica plus R-CHOP recommended for mantle cell lymphoma</strong></p>
<p>Ibrutinib (Imbruvica) in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP), submitted by AbbVie and Janssen Biotech, received a positive NICE recommendation on 23 September 2026 for previously untreated mantle cell lymphoma (MCL) in adults who are eligible for intensive chemotherapy. MCL is an aggressive B-cell non-Hodgkin lymphoma with a tendency to relapse and a historically poor long-term prognosis despite initial responsiveness to treatment. Adding ibrutinib — a Bruton’s tyrosine kinase inhibitor — to the established R-CHOP immunochemotherapy backbone targets both the B-cell receptor signalling pathway and the tumour’s microenvironment. Clinical evidence has demonstrated improved progression-free survival with the ibrutinib-containing regimen in younger, transplant-eligible patients, and the recommendation opens this intensified approach to eligible NHS patients for the first time.</p>
<h2><strong>Negative Decision</strong></h2>
<p><strong>Mitchga not recommended for prurigo nodularis</strong></p>
<p>NICE issued a negative recommendation on 9 September 2026 for nemolizumab (Mitchga), an anti-interleukin-31 receptor A monoclonal antibody developed by Galderma, Chugai/Roche, and Maruho, for the treatment of prurigo nodularis. Prurigo nodularis is a chronic and severely distressing dermatological condition characterised by intensely itchy nodules distributed across the body, driven by a neuroimmune inflammatory mechanism in which IL-31 plays a central role. The condition causes profound impairment of quality of life and has very limited licensed treatment options, making the negative decision a significant disappointment for affected patients.</p>
<p>Nemolizumab has demonstrated clinically meaningful reductions in itch intensity and lesion burden in pivotal trials, and is approved in other markets including the United States and Japan. NICE’s negative determination is likely to reflect concerns regarding cost-effectiveness at the submitted price rather than a lack of clinical efficacy. The decision may be subject to further negotiation or resubmission, and patients and clinicians will be watching closely for any appeal or managed access arrangement that could bring this treatment to NHS patients in the future.</p>
<p><em>Decisions referenced carry NICE Positive 1 or NICE Negative status, issued between 9–23 September 2026. This article is based on data from the NICE Technology Appraisal Programme for England and Wales.</em></p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/10/three-treatments-approved-by-nice-in-september-with-one-negative-decision/">Three treatments approved by NICE in September, with one negative decision</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Five treatments approved and three terminated as NICE issues August decisions</title>
		<link>https://pharmacyupdateonline.com/2026/09/five-treatments-approved-and-three-terminated-as-nice-issues-august-decisions/</link>
		
		<dc:creator><![CDATA[Peter Mas-Mollinedo]]></dc:creator>
		<pubDate>Wed, 09 Sep 2026 09:00:53 +0000</pubDate>
				<category><![CDATA[Drug Approvals]]></category>
		<category><![CDATA[Legislative & Regulatory]]></category>
		<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Practices & Services]]></category>
		<category><![CDATA[Product News]]></category>
		<category><![CDATA[allergy immunotherapy]]></category>
		<category><![CDATA[Breyanzi]]></category>
		<category><![CDATA[Calquence]]></category>
		<category><![CDATA[Dawnzera]]></category>
		<category><![CDATA[haematology]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[technology appraisal]]></category>
		<guid isPermaLink="false">https://pharmacyupdateonline.com/?p=22256</guid>

					<description><![CDATA[<p>The National Institute for Health and Care Excellence (NICE) has issued nine Technology Appraisal decisions in August 2026, comprising five positive first recommendations, one updated positive recommendation, and [&#8230;]</p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/09/five-treatments-approved-and-three-terminated-as-nice-issues-august-decisions/">Five treatments approved and three terminated as NICE issues August decisions</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The National Institute for Health and Care Excellence (NICE) has issued nine Technology Appraisal decisions in August 2026, comprising five positive first recommendations, one updated positive recommendation, and three terminations. Decisions were issued between 5 and 26 August 2026 and span cardiology, haematological oncology, immunology, respiratory medicine, and allergy. The August cycle is notable for two new combination regimens in blood cancers, a first-in-class oral therapy for hereditary angio-oedema, and the approval of a sublingual immunotherapy tablet for dust mite allergy — a relatively novel route of administration in this therapeutic area.</p>
<p>Three terminated appraisals in a single month is an unusually high number, and includes the CAR-T cell therapy Breyanzi in follicular lymphoma, a setting in which the treatment had previously received a positive recommendation in diffuse large B-cell lymphoma.</p>
<p>&nbsp;</p>
<p><strong>Positive Recommendations</strong></p>
<p><strong>Kerendia recommended for heart failure</strong></p>
<p>Finerenone (Kerendia), a non-steroidal mineralocorticoid receptor antagonist developed by Bayer HealthCare, received a positive NICE recommendation on 5 August 2026 for heart failure. Finerenone is already approved in the EU and UK for chronic kidney disease associated with type 2 diabetes, and this recommendation extends its application to heart failure, a condition in which fluid overload and neurohormonal activation play a central role in disease progression. Unlike older steroidal mineralocorticoid receptor antagonists such as spironolactone and eplerenone, finerenone has been designed to offer greater receptor selectivity, potentially reducing the risk of hyperkalaemia and other off-target effects while maintaining cardiovascular and renal protection.</p>
<p><strong>Dawnzera recommended for hereditary angio-oedema</strong></p>
<p>Donidalorsen (Dawnzera), an oral plasma kallikrein inhibitor developed by Ionis Pharmaceuticals and Otsuka, received a positive NICE recommendation on 19 August 2026 for the prevention of attacks in hereditary angio-oedema (HAE). HAE is a rare and potentially life-threatening genetic condition characterised by episodes of severe swelling affecting the skin, gastrointestinal tract, and upper airways; laryngeal attacks in particular can be fatal without prompt treatment. Donidalorsen is administered orally on a prophylactic basis, offering a significant practical advantage over existing parenteral prophylactic therapies. The recommendation represents a meaningful step forward for patients seeking a convenient, long-term preventive option.</p>
<p><strong>Calquence combinations recommended for mantle cell lymphoma and CLL</strong></p>
<p>Two separate NICE recommendations were issued on 19 August 2026 for acalabrutinib (Calquence)-based combination regimens in haematological malignancies, both submitted by AstraZeneca.</p>
<p>For mantle cell lymphoma, acalabrutinib in combination with bendamustine and rituximab (Calquence, Treanda, and Rituxan) was recommended for previously untreated patients. Mantle cell lymphoma is an aggressive B-cell non-Hodgkin lymphoma with a tendency to relapse; adding BTK inhibition to the established bendamustine-rituximab backbone offers a chemotherapy-intensified and targeted approach that has demonstrated improved outcomes in clinical trials.</p>
<p>For chronic lymphocytic leukaemia and small lymphocytic lymphoma (CLL/SLL), acalabrutinib in combination with venetoclax, with or without obinutuzumab (Calquence, Venclexta, and optionally Gazyva), was recommended. This all-oral, chemotherapy-free triplet targets three distinct mechanisms: BTK inhibition, BCL-2 inhibition, and CD20 targeting. CLL is the most common adult leukaemia in the Western world, and the combination approach represents a shift towards deeper, potentially time-limited treatment that may reduce the likelihood of resistance compared with continuous monotherapy.</p>
<p><strong>Odactra recommended for dust mite allergic rhinitis</strong></p>
<p>The sublingual allergy immunotherapy tablet for house dust mite allergy (Odactra), developed by ALK-Abello, received a positive NICE recommendation on 26 August 2026 for allergic rhinitis caused by house dust mite sensitisation. Allergen immunotherapy is the only treatment modality that addresses the underlying allergic mechanism rather than simply controlling symptoms, and sublingual tablet formulations offer a more convenient alternative to subcutaneous immunotherapy injections administered in a clinical setting. The recommendation is significant for the large number of patients with persistent, poorly controlled dust mite allergic rhinitis who do not achieve adequate symptom relief with antihistamines and intranasal corticosteroids.</p>
<p>&nbsp;</p>
<p><strong>Updated Recommendation</strong></p>
<p><strong>Itulazax receives updated recommendation for birch pollen allergy</strong></p>
<p>Betula verrucosa sublingual tablet (Itulazax), a birch pollen allergen immunotherapy developed by ALK-Abello and partnered with Torii Pharma and Shionogi, received a positive second appraisal recommendation on 25 August 2026 for allergic rhinoconjunctivitis caused by birch pollen. Itulazax is administered daily as a sublingual tablet and works by gradually desensitising the immune system to birch pollen allergens over a course of treatment typically lasting several years. The updated recommendation follows the initial positive appraisal and likely reflects revised evidence or access arrangements, and sits alongside the same cycle’s first recommendation for Odactra, underscoring growing NICE support for sublingual immunotherapy as a treatment modality across different allergen types.</p>
<p>&nbsp;</p>
<p><strong>Terminated Appraisals</strong></p>
<p><strong>Brinsupri appraisal terminated for non-CF bronchiectasis</strong></p>
<p>The appraisal of brensocatib (Brinsupri), a dipeptidyl peptidase 1 (DPP1) inhibitor developed by Insmed, was terminated on 25 August 2026 for non-cystic fibrosis bronchiectasis. Bronchiectasis is a chronic lung condition characterised by irreversible airway dilation and recurrent infections driven by neutrophilic inflammation; DPP1 inhibition reduces the activation of neutrophil serine proteases that contribute to lung damage and exacerbations. Brensocatib had been considered a significant advance in a condition with very few approved pharmacological therapies, making its termination a notable setback for patients and clinicians in this field. The reasons for termination were not specified in the available data.</p>
<p><strong>Wayrilz appraisal terminated for immune thrombocytopenic purpura</strong></p>
<p>The appraisal of rilzabrutinib (Wayrilz), an oral BTK inhibitor developed by Principia Biopharma and Sanofi, was terminated on 20 August 2026 for immune thrombocytopenic purpura (ITP). ITP is an autoimmune bleeding disorder characterised by low platelet counts resulting from immune-mediated destruction of platelets and suppression of platelet production. Rilzabrutinib targets the B-cell receptor signalling pathway and had been under investigation as an oral option for patients with persistent or chronic ITP who have failed or are intolerant of existing therapies. The termination means this treatment will not be available via the NICE appraisal route at this time.</p>
<p><strong>Breyanzi appraisal terminated for follicular lymphoma</strong></p>
<p>The appraisal of lisocabtagene maraleucel (Breyanzi), a CD19-directed CAR-T cell therapy developed by Bristol Myers Squibb, was terminated on 20 August 2026 for relapsed or refractory follicular lymphoma. This termination is particularly notable given that Breyanzi received a positive NICE recommendation for diffuse large B-cell lymphoma earlier in 2026, and is approved in other markets for follicular lymphoma. Follicular lymphoma is an indolent B-cell malignancy that, despite its relatively slow progression, frequently relapses and ultimately requires multiple lines of therapy. CAR-T cell treatment has shown strong efficacy in this setting, and the termination — likely reflecting cost-effectiveness or access agreement issues — will be disappointing for patients and their clinicians.</p>
<p><em>Decisions referenced carry NICE Positive 1, NICE Positive 2, or Terminated status, issued between 5–26 August 2026. This article is based on data from the NICE Technology Appraisal Programme for England and Wales.</em></p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/09/five-treatments-approved-and-three-terminated-as-nice-issues-august-decisions/">Five treatments approved and three terminated as NICE issues August decisions</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Nine new treatments approved by NICE in active June cycle, with two appraisals terminated</title>
		<link>https://pharmacyupdateonline.com/2026/07/nine-new-treatments-approved-by-nice-in-active-june-cycle-with-two-appraisals-terminated/</link>
		
		<dc:creator><![CDATA[Peter Mas-Mollinedo]]></dc:creator>
		<pubDate>Tue, 21 Jul 2026 04:00:04 +0000</pubDate>
				<category><![CDATA[Gastroenterology]]></category>
		<category><![CDATA[Hepatology]]></category>
		<category><![CDATA[Legislative & Regulatory]]></category>
		<category><![CDATA[Medicines & Therapeutics]]></category>
		<category><![CDATA[Mind & Brain]]></category>
		<category><![CDATA[Neurology]]></category>
		<category><![CDATA[Practices & Services]]></category>
		<category><![CDATA[drug approval]]></category>
		<category><![CDATA[hepatology]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Technology Appraisal Programme]]></category>
		<guid isPermaLink="false">https://pharmacyupdateonline.com/?p=21301</guid>

					<description><![CDATA[<p>The National Institute for Health and Care Excellence (NICE) has issued thirteen Technology Appraisal decisions in June 2026, delivering nine positive recommendations, one updated recommendation, and two terminations. [&#8230;]</p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/07/nine-new-treatments-approved-by-nice-in-active-june-cycle-with-two-appraisals-terminated/">Nine new treatments approved by NICE in active June cycle, with two appraisals terminated</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The National Institute for Health and Care Excellence (NICE) has issued thirteen Technology Appraisal decisions in June 2026, delivering nine positive recommendations, one updated recommendation, and two terminations. Oncology dominates the cycle, with approvals spanning lung, cervical, gastric, and haematological cancers. Decisions were issued between 3 and 24 June 2026 and cover both common and rare conditions affecting NHS patients in England and Wales.</p>
<p>The June cycle also includes a significant update to the existing recommendation for nusinersen in spinal muscular atrophy, as well as a positive second appraisal for a CAR-T cell therapy in large B-cell lymphoma — a treatment pathway that continues to expand within the NHS.</p>
<h3><strong>Oncology</strong></h3>
<p><strong>Tivdak recommended for cervical cancer</strong></p>
<p>Tisotumab vedotin (Tivdak), an antibody-drug conjugate developed by Genmab and Pfizer (via Seagen), received a positive NICE recommendation on 11 June 2026 for previously treated recurrent or metastatic cervical cancer. Tivdak targets tissue factor, a protein highly expressed on cervical cancer cells, and delivers a microtubule-disrupting payload directly to tumour cells. The approval addresses a population with limited options following progression on first-line platinum-based chemotherapy.</p>
<p><strong>Libtayo recommended for non-small cell lung cancer</strong></p>
<p>Cemiplimab (Libtayo), developed by Regeneron, was recommended on 16 June 2026 for previously untreated non-small cell lung cancer (NSCLC) in patients whose tumours express PD-L1. Libtayo is a PD-1 checkpoint inhibitor that restores the immune system’s ability to recognise and destroy cancer cells. The recommendation offers a further immunotherapy option in first-line NSCLC alongside existing PD-1 and PD-L1 inhibitors already available on the NHS.</p>
<p><strong>Darzalex Faspro quadruplet recommended for multiple myeloma</strong></p>
<p>NICE recommended the four-drug combination of daratumumab SC, lenalidomide, bortezomib, and dexamethasone (D-VRd; Darzalex Faspro, Revlimid, Velcade) on 24 June 2026 for newly diagnosed multiple myeloma. Submitted by Janssen Biotech, this subcutaneous daratumumab-based quadruplet regimen builds on the established VRd backbone by adding the anti-CD38 monoclonal antibody daratumumab, which has consistently demonstrated improved response rates and progression-free survival in myeloma. The approval positions D-VRd as a potential new standard of care for eligible transplant-eligible and ineligible patients.</p>
<p><strong>Hansizhuang recommended for extensive-stage small cell lung cancer</strong></p>
<p>Serplulimab (Hansizhuang), in combination with chemotherapy and submitted by Shanghai Henlius Biotech and Fosun Pharma, received a positive recommendation on 18 June 2026 for extensive-stage small cell lung cancer (ES-SCLC). Small cell lung cancer is an aggressive malignancy with a historically poor prognosis, and first-line chemoimmunotherapy has become the standard approach following earlier immunotherapy approvals in this setting. Serplulimab is an anti-PD-1 antibody, and its recommendation provides a further immunotherapy option for patients presenting with extensive disease.</p>
<p><strong>Imfinzi plus FLOT chemotherapy recommended for gastric and gastro-oesophageal junction cancer</strong></p>
<p>Durvalumab (Imfinzi) in combination with FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) was recommended by NICE on 3 June 2026 as a neoadjuvant and adjuvant treatment for resectable gastric cancer and gastro-oesophageal junction cancer (GEJC). Developed by AstraZeneca, the perioperative regimen adds PD-L1 blockade to an established chemotherapy backbone, reflecting evidence that immunotherapy can improve surgical outcomes and reduce the risk of recurrence in patients with potentially curable disease.</p>
<p><strong>Breyanzi receives positive recommendation for diffuse large B-cell lymphoma</strong></p>
<p>Lisocabtagene maraleucel (Breyanzi), a CD19-directed CAR-T cell therapy developed by Bristol Myers Squibb (via Juno Therapeutics and Celgene), received a positive second appraisal recommendation on 3 June 2026 for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). CAR-T therapies represent a complex and highly personalised treatment modality in which a patient’s own T cells are engineered to recognise and destroy cancer cells. The updated recommendation reflects revised cost-effectiveness evidence and expands NHS access to this potentially curative one-time treatment for patients who have failed two or more prior lines of therapy.</p>
<h2><strong>Respiratory &amp; Cardiovascular</strong></h2>
<p><strong>Nucala recommended for eosinophilic COPD</strong></p>
<p>Mepolizumab (Nucala), developed by GSK, received a positive recommendation on 17 June 2026 for eosinophilic chronic obstructive pulmonary disease (COPD). Nucala is an anti-interleukin-5 monoclonal antibody already established in severe eosinophilic asthma, and this approval extends its indication to a subset of COPD patients characterised by elevated blood eosinophil counts. It represents an important development in COPD management, which has traditionally relied on bronchodilators and inhaled corticosteroids, by targeting an underlying inflammatory mechanism in eligible patients.</p>
<p><strong>Winrevair recommended for pulmonary arterial hypertension</strong></p>
<p>Sotatercept (Winrevair), developed by Acceleron and Merck, received a positive NICE recommendation on 3 June 2026 for pulmonary arterial hypertension (PAH). Sotatercept is an activin signalling inhibitor — a first-in-class mechanism of action in PAH — that addresses vascular remodelling, the underlying pathological process driving the progressive increase in pulmonary artery pressure that characterises this condition. Current PAH therapies largely target vasodilation; sotatercept’s distinct mechanism makes it a meaningful addition to the treatment armamentarium, particularly in combination with existing background therapy.</p>
<p><strong>Nexlizet recommended for dyslipidaemia</strong></p>
<p>The combination of bempedoic acid and ezetimibe (Nexlizet), submitted by Esperion Therapeutics and Daiichi Sankyo, was recommended on 24 June 2026 for dyslipidaemia in patients unable to tolerate statins or with an inadequate response to statin therapy. Bempedoic acid inhibits ATP-citrate lyase, an enzyme upstream of HMG-CoA reductase in the cholesterol biosynthesis pathway, while ezetimibe reduces intestinal cholesterol absorption. The combination provides a non-statin LDL-lowering option for a patient group that includes those with statin intolerance, an issue frequently encountered in clinical practice.</p>
<h3><strong>Hepatology &amp; Gastroenterology</strong></h3>
<p><strong>Livdelzi recommended for primary biliary cholangitis</strong></p>
<p>Seladelpar (Livdelzi), developed by Gilead Sciences and CymaBay Therapeutics, received a positive recommendation on 24 June 2026 for primary biliary cholangitis (PBC), a rare chronic autoimmune liver disease that can lead to cirrhosis if inadequately treated. Seladelpar is a selective PPAR-delta agonist that reduces the production of bile acids and suppresses biliary inflammation. The recommendation is significant for patients who have had an inadequate response to or cannot tolerate ursodeoxycholic acid, which has long been the only licensed first-line treatment for PBC in the UK.</p>
<h3><strong>Neurology &amp; Paediatrics</strong></h3>
<p><strong>Spinraza recommendation updated for spinal muscular atrophy</strong></p>
<p>Nusinersen (Spinraza), developed by Biogen and Ionis Pharmaceuticals, received an updated NICE recommendation on 4 June 2026 for spinal muscular atrophy (SMA). SMA is a rare and often severe inherited neuromuscular disease caused by mutations in the SMN1 gene. Spinraza was among the first disease-modifying treatments to be approved for SMA and works by modifying splicing of the SMN2 gene to increase production of functional SMN protein. The updated recommendation likely reflects revised clinical or cost-effectiveness evidence, potentially expanding eligible patient groups or amending existing access criteria.</p>
<h3><strong>Terminated Appraisals</strong></h3>
<p><strong>Inluriyo appraisal terminated for ER-positive breast cancer</strong></p>
<p>The appraisal of imlunestrant (Inluriyo), an oral selective oestrogen receptor degrader (SERD) submitted by Eli Lilly and Loxo Oncology, was terminated on 18 June 2026 for oestrogen receptor-positive, HER2-negative breast cancer with ESR1 mutation. ESR1 mutations are a recognised mechanism of resistance to aromatase inhibitors and represent a clinically important unmet need. The reasons for termination were not specified in the available data, though terminated appraisals typically reflect a withdrawal by the company or an inability to agree a managed access arrangement.</p>
<p><strong>Anktiva appraisal terminated for BCG-unresponsive bladder cancer</strong></p>
<p>The appraisal of nogapendekin alfa inbakicept (Anktiva), submitted by ImmunityBio and Accord Healthcare for BCG-unresponsive non-muscle-invasive bladder cancer, was terminated on 4 June 2026. BCG-unresponsive disease represents a challenging clinical situation in which patients have failed intravesical BCG immunotherapy — the standard treatment for high-risk non-muscle-invasive bladder cancer — and face a choice between radical cystectomy or further bladder-sparing treatments. The termination leaves this patient population without a new approved option via NICE at this time.</p>
<p><em>Decisions referenced carry NICE Positive 1, NICE Positive 2, NICE Update 1, or Terminated status, issued between 3–24 June 2026. This article is based on data from the NICE Technology Appraisal Programme for England and Wales.</em></p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/07/nine-new-treatments-approved-by-nice-in-active-june-cycle-with-two-appraisals-terminated/">Nine new treatments approved by NICE in active June cycle, with two appraisals terminated</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Nineteen further treatments recommended as CHMP continues active approvals cycle</title>
		<link>https://pharmacyupdateonline.com/2026/07/nineteen-further-treatments-recommended-as-chmp-continues-active-approvals-cycle/</link>
		
		<dc:creator><![CDATA[Peter Mas-Mollinedo]]></dc:creator>
		<pubDate>Mon, 20 Jul 2026 04:00:02 +0000</pubDate>
				<category><![CDATA[Drug Approvals]]></category>
		<category><![CDATA[Legislative & Regulatory]]></category>
		<category><![CDATA[Mind & Brain]]></category>
		<category><![CDATA[Neurology]]></category>
		<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Practices & Services]]></category>
		<category><![CDATA[Product News]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[drug approval]]></category>
		<category><![CDATA[European Commission]]></category>
		<category><![CDATA[European Medicines Agency]]></category>
		<category><![CDATA[opinion cycle]]></category>
		<guid isPermaLink="false">https://pharmacyupdateonline.com/?p=21298</guid>

					<description><![CDATA[<p>The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a further nineteen positive recommendations spanning oncology, neurology, infectious disease, dermatology, cardiovascular medicine, diabetes, [&#8230;]</p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/07/nineteen-further-treatments-recommended-as-chmp-continues-active-approvals-cycle/">Nineteen further treatments recommended as CHMP continues active approvals cycle</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a further nineteen positive recommendations spanning oncology, neurology, infectious disease, dermatology, cardiovascular medicine, diabetes, and rare conditions. The batch includes treatments for conditions ranging from Parkinson’s disease and Rett syndrome to HIV, monkeypox, and multiple myeloma, as well as two biosimilar approvals that will support wider patient access to established therapies.</p>
<p>Oncology and dermatology feature prominently in this cycle, with notable recommendations for novel antibody-drug conjugates, a new JAK inhibitor indication, and an innovative combination approach in multiple myeloma. The cycle also includes three vaccine recommendations addressing chikungunya, meningococcal disease, influenza, and orthopoxvirus infections.</p>
<h3><strong>Oncology</strong></h3>
<p><strong>Datroway recommended for triple-negative breast cancer</strong></p>
<p>Datopotamab deruxtecan (Datroway), an antibody-drug conjugate developed by Daiichi Sankyo and AstraZeneca, has received a positive CHMP recommendation for triple-negative breast cancer (TNBC). TNBC remains one of the most challenging breast cancer subtypes to treat, given its lack of hormone receptor and HER2 expression. Datroway targets TROP2, a protein overexpressed in many epithelial tumours, and delivers a cytotoxic payload selectively to cancer cells, offering a more targeted approach than conventional chemotherapy.</p>
<p><strong>Tecvayli and Darzalex Faspro combination recommended for multiple myeloma</strong></p>
<p>Johnson &amp; Johnson has received a CHMP recommendation for the combination of teclistamab and daratumumab (Tecvayli and Darzalex Faspro) for multiple myeloma. Teclistamab is a bispecific T-cell engager targeting BCMA and CD3, while daratumumab is a well-established anti-CD38 monoclonal antibody. Combining the two mechanisms in a chemotherapy-free regimen represents a significant advance in the treatment of relapsed or refractory multiple myeloma, a condition that typically requires repeated lines of therapy over time.</p>
<p><strong>Jaypirca recommended for chronic lymphocytic leukaemia</strong></p>
<p>Pirtobrutinib (Jaypirca), a non-covalent BTK inhibitor developed by Loxo Oncology at Lilly and Eli Lilly, has been recommended for chronic lymphocytic leukaemia and small lymphocytic lymphoma (CLL/SLL). Unlike covalent BTK inhibitors such as ibrutinib, pirtobrutinib is designed to remain active in patients who have developed resistance mutations, offering a treatment option for a population with limited alternatives following prior BTK inhibitor therapy.</p>
<p><strong>Denosumab biosimilar recommended for bone complications in cancer</strong></p>
<p>Denosumab Ascend, a biosimilar of denosumab developed by Ascend GmbH, has received a CHMP recommendation for the prevention of skeletal-related events in patients with bone metastases and for giant cell tumour of bone. The availability of a biosimilar version of this widely used bone-targeted agent is expected to improve patient access and reduce costs for health systems across the EU.</p>
<p><strong>Pegfilgrastim biosimilar recommended for neutropenia</strong></p>
<p>Nylaspeg, a biosimilar of pegfilgrastim submitted by Qilu Pharmaceuticals, has received a positive recommendation for chemotherapy-induced neutropenia. Pegfilgrastim is routinely used to stimulate white blood cell production and reduce the risk of febrile neutropenia in cancer patients receiving myelosuppressive chemotherapy. The biosimilar recommendation supports continued access to this supportive care treatment at competitive cost.</p>
<h3><strong>Dermatology &amp; Immunology</strong></h3>
<p><strong>Rinvoq recommended for vitiligo and alopecia areata</strong></p>
<p>AbbVie’s upadacitinib (Rinvoq), a selective JAK1 inhibitor, has received two separate CHMP recommendations expanding its indications into dermatology: one for vitiligo and one for alopecia areata. Vitiligo is a chronic autoimmune condition causing depigmentation of the skin, while alopecia areata results in patchy or total hair loss driven by immune-mediated attack on hair follicles. Both conditions have historically lacked effective systemic treatments, and these recommendations follow growing clinical evidence supporting JAK inhibition as a mechanism of action in autoimmune skin diseases. Rinvoq is already approved for several inflammatory conditions including rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis.</p>
<p><strong>Opzelura recommended for atopic dermatitis</strong></p>
<p>Ruxolitinib cream (Opzelura), developed by Incyte Corporation and Maruho, has received a CHMP recommendation for atopic dermatitis (eczema). Opzelura is a topical JAK1/JAK2 inhibitor that provides targeted anti-inflammatory activity at the site of application, offering an alternative to topical corticosteroids for patients with mild to moderate disease. The recommendation addresses a highly prevalent condition that places significant quality of life burden on patients, particularly those with disease affecting visible areas of skin.</p>
<h3><strong>Neurology &amp; Paediatrics</strong></h3>
<p><strong>Daybue recommended for Rett syndrome</strong></p>
<p>Trofinetide (Daybue), developed by Acadia Pharmaceuticals, has received a CHMP recommendation for Rett syndrome, a rare and severe neurodevelopmental disorder caused by mutations in the MECP2 gene, which predominantly affects girls. The condition leads to progressive loss of motor and communication skills and has no approved disease-modifying treatments in the EU. Daybue is a synthetic analogue of the naturally occurring tripeptide GPE (glycine-proline-glutamate) and represents the first pharmacological treatment specifically developed for this condition to receive a positive EU recommendation.</p>
<p><strong>Crexont recommended for Parkinson’s disease</strong></p>
<p>A prolonged-release combination of carbidopa and levodopa (Crexont), submitted by Amneal Pharmaceuticals and Zambon, has been recommended for Parkinson’s disease. Levodopa remains the cornerstone of Parkinson’s pharmacotherapy, but standard formulations are associated with motor fluctuations and wearing-off effects as the disease progresses. The extended-release formulation aims to provide more consistent plasma drug levels throughout the day, potentially reducing the frequency and severity of motor complications in patients with advanced disease.</p>
<p><strong>Stelara recommended for paediatric ulcerative colitis</strong></p>
<p>Ustekinumab (Stelara), developed by Johnson &amp; Johnson, has received a CHMP recommendation for paediatric ulcerative colitis. Ustekinumab is an interleukin-12 and interleukin-23 inhibitor already established in adult inflammatory bowel disease and psoriasis. This paediatric recommendation addresses a significant unmet need in younger patients with moderate to severe ulcerative colitis who have an inadequate response to conventional therapy.</p>
<h3><strong>Infectious Diseases &amp; Vaccines</strong></h3>
<p><strong>Ixchiq recommended for chikungunya fever</strong></p>
<p>Ixchiq, a live-attenuated chikungunya vaccine developed by Valneva SE and Instituto Butantan, has received a positive CHMP recommendation. Chikungunya is a mosquito-borne viral illness characterised by fever and severe joint pain, with outbreaks increasingly reported in southern Europe due to the northward spread of the Aedes albopictus mosquito. The approval of a preventive vaccine represents an important public health tool as the geographical range of the disease continues to expand.</p>
<p><strong>MenQuadfi recommended for meningococcal disease</strong></p>
<p>MenQuadfi, a conjugate vaccine targeting meningococcal serogroups A, C, W, and Y, developed by Sanofi, has received a CHMP recommendation. Meningococcal disease can cause life-threatening bacterial meningitis and septicaemia, particularly in infants, young children, and adolescents. The conjugate formulation is designed to produce a robust and long-lasting immune response and is suitable for use in paediatric populations.</p>
<p><strong>Imvanex recommended for monkeypox and orthopoxvirus infections</strong></p>
<p>Bavarian Nordic’s Imvanex, a modified vaccinia Ankara-based vaccine, has received a CHMP recommendation for protection against monkeypox (mpox) and other orthopoxvirus infections. Imvanex was already authorised for smallpox prevention in the EU and was used extensively during the 2022 mpox outbreak. This recommendation formalises its indication for mpox and broader orthopoxvirus prophylaxis, reflecting the continued public health relevance of the product.</p>
<p><strong>Aujemflu recommended for influenza</strong></p>
<p>Aujemflu, an adjuvanted trivalent influenza vaccine developed by Seqirus/CSL, has received a CHMP recommendation for the prevention of influenza. The adjuvanted formulation is designed to enhance immunogenicity, particularly in older adults and immunocompromised populations where vaccine responses may be suboptimal. The recommendation adds to the existing portfolio of seasonal influenza vaccines available to EU member states.</p>
<p><strong>Symtuza and Prezcobix recommended for HIV</strong></p>
<p>Two HIV antiretroviral regimens have received CHMP recommendations. Symtuza — a single-tablet combination of darunavir, emtricitabine, cobicistat, and tenofovir alafenamide (TAF), developed by Johnson &amp; Johnson and Gilead Sciences — offers a complete one-tablet-once-daily regimen for HIV-1 infection. Separately, Prezcobix — a combination of darunavir and cobicistat developed by Janssen Therapeutics — provides a boosted protease inhibitor backbone for use in combination with other antiretrovirals. Both recommendations likely reflect updated indications or label revisions for these established regimens.</p>
<h3><strong>Cardiovascular &amp; Diabetes</strong></h3>
<p><strong>Leqvio recommended for hypercholesterolaemia</strong></p>
<p>Inclisiran (Leqvio), a small interfering RNA (siRNA) therapy developed by Novartis, has received a CHMP recommendation for hypercholesterolaemia. Inclisiran works by inhibiting the production of PCSK9, a protein that reduces the liver’s ability to clear LDL cholesterol from the blood. Administered just twice yearly by subcutaneous injection, inclisiran offers a highly differentiated dosing schedule compared with daily oral statins or monthly PCSK9 inhibitor antibodies, which may improve adherence in patients requiring long-term lipid-lowering therapy.</p>
<p><strong>Onswik recommended for type 2 diabetes</strong></p>
<p>Insulin efsitora alfa (Onswik), a once-weekly basal insulin analogue developed by Eli Lilly, has received a positive CHMP recommendation for type 2 diabetes. The treatment represents a significant step forward in insulin therapy, offering a weekly injection as an alternative to the daily or twice-daily basal insulin regimens that many patients find burdensome. A reduced injection frequency is expected to support better adherence and patient quality of life, particularly in the early stages of insulin initiation.</p>
<p><em>All nineteen decisions listed carry CHMP Recommended status. CHMP recommendations are subject to final marketing authorisation by the European Commission. This article is based on data from the European Medicines Agency CHMP opinion cycle.</em></p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/07/nineteen-further-treatments-recommended-as-chmp-continues-active-approvals-cycle/">Nineteen further treatments recommended as CHMP continues active approvals cycle</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Have Pharma gone Webinar crazy!?</title>
		<link>https://pharmacyupdateonline.com/2021/04/have-pharma-gone-webinar-crazy/</link>
		
		<dc:creator><![CDATA[Peter Mas-Mollinedo]]></dc:creator>
		<pubDate>Sun, 25 Apr 2021 01:00:51 +0000</pubDate>
				<category><![CDATA[Conference Highlights]]></category>
		<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Practices & Services]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[webinar]]></category>
		<guid isPermaLink="false">https://www.pharmacyupdate.online/?p=647</guid>

					<description><![CDATA[<p>With the outbreak of the Pandemic and the lingering worries of COVID-19 pharmaceutical sales and marketing has taken a hit. There are no live conferences that health care [&#8230;]</p>
<p>The post <a href="https://pharmacyupdateonline.com/2021/04/have-pharma-gone-webinar-crazy/">Have Pharma gone Webinar crazy!?</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></description>
										<content:encoded><![CDATA[With the outbreak of the Pandemic and the lingering worries of COVID-19 pharmaceutical sales and marketing has taken a hit. There are no live conferences that health care professionals can physically visit and meeting a doctor in sales call is still a long way off for many countries.



Over the last few months webinar activities have increased substantially. A remote piece of activity where a key opinion leader will discuss and or be interviewed about their chosen subject. On the face of it this may sound like a good idea, allowing messages about the product and disease to be circulated thus bypassing the risks associated with COVID-19. But let us take a more detailed look.

 

As a company (IMI) we help pharmaceutical companies spread the message through our positive opt-in email database. We were one of the first companies in the market to offer this facility, and we have over 14 years’ experience, so we know what a good email looks like and more importantly we know what doesn’t work.

 

Webinar stats

 

<strong>Statistics</strong>

 

Email in comparison to webinars, continues to dominate. On a scale of 1-5, email ranked 4.46 and was one of the top tools for promotion.

 

Scoring a 2.77 out of 5, social media is the second most widely used promotional tool for webinars.

 

In order to make a webinar campaign effective, 3 is the magic number in terms of email campaigns deployed per webinar.

 

Experience shows that response rates are highest during the 2 weeks before a webinar. So it is important to get those invitations out. 30% to 40% of visitors to a webinar landing page, register for the event. Send at least one reminder the day before event for best results and limit registration forms to 5-7 questions.

 

<strong>Elephant in the room.</strong>

 

If you were faced with the two options below which would you choose?<strong>
</strong>

 

<strong>OPTION 1</strong>

 
<ul class="wp-block-list">
 	<li>Receive an email</li>
 	<li>click on webinar registration</li>
 	<li>confirm that you are a health care professional</li>
 	<li>complete 5-7 questions to register</li>
 	<li>Put the date and time in your diary.</li>
 	<li>On the day of the webinar open confirmation email and listen for 30-45 mins.</li>
</ul>
 

<strong>OPTION 2</strong>

 
<ul class="wp-block-list">
 	<li>Receive an email that has a video already embedded in the content that contains 5-6 carefully structured questions being answered by a key opinion leader.</li>
</ul>
 

I am sure that we are not alone in being incredibly busy with email marketing over the last 6 months and IMI’s September booking slots are almost full. We are extremely careful with our HCP database and do NOT bombard the list with numerous webinar invitations. Other suppliers have a different approach and the webinar landscape is becoming increasingly congested. Take note of the elephant in the room and provide information in a quick easy to access way that will keep the reader engaged.

 

If you are committed to a webinar why not take option 2 above after the event. You will not be disappointed with the results.

<p>The post <a href="https://pharmacyupdateonline.com/2021/04/have-pharma-gone-webinar-crazy/">Have Pharma gone Webinar crazy!?</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
